The central role of Th2 cytokines in AD pathogenesis is underscored by the clinical efficacy of targeted biologics such as dupilumab, a monoclonal antibody directed against the IL-4 receptor alpha subunit (IL-4Rα), thereby inhibiting both IL-4 and IL-13 signaling [20,21]. Here, IL13 is linked to Alzheimer disease.